Skip to content

Effects of a Legume-rich Diet in the Context of the Planetary Health Diet Compared to a Western-oriented Dietary Pattern in Participants with Increased Cardiometabolic Risk

Effects of a Legume-rich Diet in the Context of the Planetary Health Diet Compared to a Western-oriented Dietary Pattern in Women and Men At Increased Risk of Cardiovascular and Neurodegenerative Diseases

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06700954
Acronym
LeguPlan_2
Enrollment
100
Registered
2024-11-22
Start date
2025-01-06
Completion date
2025-12-31
Last updated
2024-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases

Brief summary

The aim of the study is to systematically investigate the effects of a diet enriched with legumes in a dietary pattern approach (Planetary Health Diet) compared to a control diet low in legumes in older people with a risk phenotype for cardiovascular and neurodegenerative diseases. For this purpose, a controlled, six-week nutritional intervention study will be carried out in a parallel design. A total of 100 subjects (aged 50 - 75 years) will be randomly assigned to one of two intervention groups: i) a legume-rich diet based on the Planetary Health Diet, with a focus on plant protein, ii) a diet based on the Western dietary pattern including animal protein sources (= control diet). The target variables include parameters of lipid, glucose and insulin metabolism as well as biomarkers of inflammation and endothelial activation, proteomics and neurodegeneration markers. Furthermore, pulse wave velocity is measured to assess vascular function and neuropsychological target variables (e.g. hunger, satiety) are recorded using questionnaires.

Detailed description

The aim of the study is to systematically investigate the effects of a diet enriched with legumes in the dietary pattern approach (Planetary Health Diet) compared to a control diet low in legumes in older people with a risk phenotype for cardiovascular and neurodegenerative diseases. For this purpose, a controlled, six-week nutritional intervention study will be carried out in a parallel design. A total of 100 subjects (aged 50 - 75 years) will be randomly assigned to one of two intervention groups: i) a legume-rich diet based on the Planetary Health Diet, with a focus on plant protein, ii) a diet based on the Western dietary pattern including animal protein sources (= control diet). The target variables include parameters of lipid, glucose and insulin metabolism as well as biomarkers of inflammation and endothelial activation, proteomics and neurodegeneration markers. Furthermore, pulse wave velocity is measured to assess vascular function and neuropsychological target variables (e.g. hunger, satiety) are recorded using questionnaires. The subjects come to the study center for examination before the start of the intervention (visit 1), after three weeks (mid-intervention, visit 2) and after six weeks (end of intervention, visit 3).

Interventions

OTHERlegume-rich Planetary Health Diet

legume-rich diet based on the Planetary Health Diet, with a focus on vegetable protein

OTHERcontrol diet based on Western Diet low in legumes

diet based on the Western dietary pattern including animal protein sources (= control diet)

Sponsors

Federal Ministry of Food and Agriculture (BMEL)
CollaboratorUNKNOWN
Federal Office of Agriculture and Food (BLE)
CollaboratorUNKNOWN
University of Bonn
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* written informed consent * Non-smoking * BMI: 27 - 34,9 kg/m2 * Waist circumference (women ≥ 80 cm, men ≥ 94 cm) * Systolic blood pressure: ≥ 120 mmHg, diastolic blood pressure: ≥ 80 mmHg * At least one of the following criteria: * Fasting triglycerides in serum: ≥ 150 mg/dL * Fasting LDL cholesterol in serum ≥160 mg/dL * Fasting HDL-Cholesterol in serum: women \< 50 mg/dl, men \< 40 mg/dL * Fasting glucose in plasma: ≥ 100 mg/dL * CRP in serum 0,2-3 mg/dL

Exclusion criteria

* food intolerances and allergies (especially legumes) * Smoking * malabsorption syndromes * thyroid diseases * impaired renal function * chronic liver disease * heart failure * myocardial infarction * insulin-dependent diabetes mellitus * chronic inflammatory diseases * tumors * anemia * immunosuppression * intake of supplements (e.g., fish oil) * Participation in another study * other

Design outcomes

Primary

MeasureTime frameDescription
Pameters of glucose metabolism in bloodpostprandial period of 2 hours (t = 0,2) in week 1 and week 6 of interventionGlucose (mg/dL)

Secondary

MeasureTime frameDescription
Parameters of glucose metabolism in bloodpostprandial period of 2 hours (t = 0,2) in week 1 and week 6 of interventionInsulin (nmol/L)
Parameters of lipid metabolism in bloodFasting (t=0) in week 1 and week 6 of interventionTriglycerides (mg/dL)
Blood ureaFasting (t=0) in week 1 and week 6 of interventionUrea in blood (mg/dL)
Uric acid in bloodFasting (t=0) in week 1 and week 6 of interventionUric acid in blood (mg/dL)
Parameters of endothelial function in bloodFasting (t=0) in week 1 and week 6 of interventionADMA (µmo/L)
Parameters of inflammation in bloodFasting (t=0) in week 1 and week 6 of interventionIL-6 (pg/mL)
Parameters of Hunger and Satiety in bloodFasting (t=0) in week 1 and week 6 of interventionGhrelin (pg/mL)
Endothelial functionFasting (t=0) in week 1 and week 6 of interventionpulse wave velocity (m/s) with the vicorder device
Liver enzymesFasting (t=0) in week 1 and week 6 of interventionGGT (U/L)
Small blood countFasting (t=0) in week 1 and week 6 of intervention
ProteomicsFasting (t=0) in week 1 and week 6 of intervention
AdiponectinFasting (t=0) in week 1 and week 6 of interventionAdiponectin (µg/ml)
Parameters oft the antioxidant systemFasting (t=0) in week 1 and week 6 of interventionvitamin C
trace elementsFasting (t=0) in week 1 and week 6 of interventioniron
Neurodegenerative markersFasting (t=0) in week 1 and week 6 of interventionGFAP
Blood pressureFasting (t=0) in week 1 and week 6 of interventionBlood pressure (mmHg)
REEFasting (t=0) in week 1 and week 6 of interventionREE (kcal/24h)
Anthropometic measurementsFasting (t=0) in week 1 and week 6 of interventionweight (kg)
Neuropsychological parametersFasting (t=0) in week 1 and week 6 of interventionAssessment of memory via a validated neuropsychological questionaire (paper pencil, e.g. higher reproduction of memorised visual and verbal information = better memory; visual part: maximum points: 31 = all visual information memorised, minimum points: 0 = no visual information memorised; verbal part: maximum points: 24 = all verbal information memorised, minimum points: 0 = no verbal information memorised)
Fecal fatty acid profileFasting (t=0) in week 1 and week 6 of intervention
FerritinFasting (t=0) in week 1 and week 6 of interventionFerritin (µg/L)

Countries

Germany

Contacts

Primary ContactSarah Egert, Prof PhD
s.egert@uni-bonn.de+ 49 (0) 228 / 73 59 53

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026